Αποτελέσματα Αναζήτησης
1 Ιουλ 2020 · Dr. Aditya Bardia: A 62-year-old woman was evaluated at this hospital after she had identified a mass in her left breast, confirmed by her physician on physical examination, during the pandemic...
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate...
- 20-Year Risks of Breast-Cancer Recurrence After Stopping Endocrine Therapy at 5 Years
During the study period from 5 to 20 years, the absolute...
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Breast cancer is the most common cancer in women in the...
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
The RASTER (Microarray Prognostics in Breast Cancer) study...
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
1 Ιαν 2011 · In this case study, a women aged 40 was diagnosed with Metastatic breast cancer. Metastatic breast cancer is a complex multi-stage disease involving the expansion of cancerous cells from the...
5 Ιουν 2024 · A 45-year-old woman was evaluated in the oncology clinic of the hospital because of metastatic triple-negative breast cancer that had progressed despite chemotherapy. Management decisions were...
BREAST CANCER STUDY CASE. Scenario A . Carol Edwards, a 39 year-old premenopausal woman, had a screening mammogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam.
1 Δεκ 2019 · PDF | Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70-80% of patients with early-stage, non-metastatic disease.... | Find, read and cite all the...
Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection.
We conducted a case-case analysis of women treated for invasive breast cancer at the University of California San Francisco Breast Care Center (UCSF BCC). This study included only women with a confirmed diagnosis of invasive breast cancer previously undergoing standard mammography screening.
